Literature DB >> 12185622

[Polypoidal choroidal vasculopathy in a patient with a melanocytoma of the optic nerve].

M Nicolás El-Haddad1, F Clement Fernández, E Pérez-Salvador, C Martín Reyes.   

Abstract

PURPOSE/
METHOD: The choroidal neovascularization (CNV) may be associated with several types of choroidal tumors. The polypoidal choroidal vasculopathy (PVC) is a variant of the choroidal neovascularization. We present a case of PCV associated with melanocytoma of the optic nerve. RESULTS/
CONCLUSIONS: Although we cannot rule out that these two entities are independent of each other, the reported cases of choroidal tumors with CNV, the publication of a similar case and the epidemiological similarity between melanocytoma and PCV leads us to think that they may be related. We confirm the efficacy of laser argon treatment (Arch Soc Esp Oftalmol 2002; 77: 455-458).

Entities:  

Mesh:

Year:  2002        PMID: 12185622

Source DB:  PubMed          Journal:  Arch Soc Esp Oftalmol        ISSN: 0365-6691


  4 in total

1.  Bevacizumab for the treatment of a complicated posterior melanocytoma.

Authors:  Julio A Urrets-Zavalia; Nicolas Crim; Evangelina Esposito; Leandro Correa; M Eugenia Gonzalez-Castellanos; Dana Martinez
Journal:  Clin Ophthalmol       Date:  2015-03-06

2.  Management of Choroidal Neovascularization Associated with Optic Disc Melanocytoma with Intravitreal Aflibercept: A Case Report and Review of the Literature.

Authors:  Hany S Hamza; Magdy Moussa; Abdelrahman M Elhusseiny
Journal:  Case Rep Ophthalmol Med       Date:  2019-08-07

3.  Optic disk melanocytoma associated with polypoidal choroidal vasculopathy lesions, after combination treatment of photodynamic therapy and intavitreal aflibercept (Eylea), a case report.

Authors:  Alexandros Rouvas; Nikolaos S Gouliopoulos; Marilita M Moschos; Panagiotis Theodossiadis
Journal:  BMC Ophthalmol       Date:  2018-10-12       Impact factor: 2.209

Review 4.  Melanocytoma of the optic disk: A review.

Authors:  Jerry A Shields; Hakan Demirci; Arman Mashayekhi; Ralph C Eagle; Carol L Shields
Journal:  Indian J Ophthalmol       Date:  2019-12       Impact factor: 1.848

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.